WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease

Authors

  • David A. Price,

    1. Department of Pharmacology, University of Texas Health Science Center, 7703 Floyd Curl Drive - MC 6205, San Antonio, TX 78229-3900, USA
    Search for more papers by this author
    • *

      Present address: Department of Pharmacology, University of Colorado Denver, Denver, CO, USA.

  • Alex A. Martinez,

    1. Department of Pharmacology, University of Texas Health Science Center, 7703 Floyd Curl Drive - MC 6205, San Antonio, TX 78229-3900, USA
    Search for more papers by this author
  • Alexandre Seillier,

    1. Department of Pharmacology, University of Texas Health Science Center, 7703 Floyd Curl Drive - MC 6205, San Antonio, TX 78229-3900, USA
    Search for more papers by this author
  • Wouter Koek,

    1. Department of Pharmacology, University of Texas Health Science Center, 7703 Floyd Curl Drive - MC 6205, San Antonio, TX 78229-3900, USA
    2. Department of Psychiatry, University of Texas Health Science Center, San Antonio, TX, USA
    Search for more papers by this author
  • Yolanda Acosta,

    1. Department of Pharmacology, University of Texas Health Science Center, 7703 Floyd Curl Drive - MC 6205, San Antonio, TX 78229-3900, USA
    Search for more papers by this author
  • Elizabeth Fernandez,

    1. Department of Pharmacology, University of Texas Health Science Center, 7703 Floyd Curl Drive - MC 6205, San Antonio, TX 78229-3900, USA
    2. Geriatric Research, Education and Clinical Center, South Texas Veterans Health Care System, San Antonio, TX, USA
    Search for more papers by this author
  • Randy Strong,

    1. Department of Pharmacology, University of Texas Health Science Center, 7703 Floyd Curl Drive - MC 6205, San Antonio, TX 78229-3900, USA
    2. Geriatric Research, Education and Clinical Center, South Texas Veterans Health Care System, San Antonio, TX, USA
    Search for more papers by this author
  • Beat Lutz,

    1. Institute of Physiological Chemistry and Pathobiochemistry, Johannes Gutenberg-University, Mainz, Germany
    Search for more papers by this author
  • Giovanni Marsicano,

    1. NeuroCentre Magendie, U682 INSERM, University of Bordeaux 2, Avenir Group, Bordeaux, France
    Search for more papers by this author
  • James L. Roberts,

    1. Department of Pharmacology, University of Texas Health Science Center, 7703 Floyd Curl Drive - MC 6205, San Antonio, TX 78229-3900, USA
    2. Audie L. Murphy Veteran Affairs Medical Center, San Antonio, TX, USA
    Search for more papers by this author
  • Andrea Giuffrida

    1. Department of Pharmacology, University of Texas Health Science Center, 7703 Floyd Curl Drive - MC 6205, San Antonio, TX 78229-3900, USA
    Search for more papers by this author

Dr Andrea Giuffrida, as above.
E-mail: giuffrida@uthscsa.edu

Abstract

Parkinson’s disease (PD) is characterized by the progressive loss of nigrostriatal dopamine neurons leading to motor disturbances and cognitive impairment. Current pharmacotherapies relieve PD symptoms temporarily but fail to prevent or slow down the disease progression. In this study, we investigated the molecular mechanisms by which the non-selective cannabinoid receptor agonist WIN55,212-2 (WIN) protects mouse nigrostriatal neurons from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity and neuroinflammation. Stereological analyses showed that chronic treatment with WIN (4 mg/kg, intraperitoneal), initiated 24 h after MPTP administration, protected against MPTP-induced loss of tyrosine hydroxylase-positive neurons in the substantia nigra pars compacta independently of CB1 cannabinoid receptor activation. The neuroprotective effect of WIN was accompanied by increased dopamine and 3,4-dihydroxyphenylacetic acid levels in the substantia nigra pars compacta and dorsal striatum of MPTP-treated mice. At 3 days post-MPTP, we found significant microglial activation and up-regulation of CB2 cannabinoid receptors in the ventral midbrain. Treatment with WIN or the CB2 receptor agonist JWH015 (4 mg/kg, intraperitoneal) reduced MPTP-induced microglial activation, whereas genetic ablation of CB2 receptors exacerbated MPTP systemic toxicity. Furthermore, chronic WIN reversed MPTP-associated motor deficits, as revealed by the analysis of forepaw step width and percentage of faults using the inverted grid test. In conclusion, our data indicate that agonism at CB2 cannabinoid receptors protects against MPTP-induced nigrostriatal degeneration by inhibiting microglial activation/infiltration and suggest that CB2 receptors represent a new therapeutic target to slow the degenerative process occurring in PD.

Ancillary